Susquehanna Fundamental Investments’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $381K | Sell |
50,434
-42,955
| -46% | -$325K | 0.01% | 587 |
|
|
2025
Q1 | $516K | Buy |
93,389
+75,043
| +409% | +$414K | 0.01% | 832 |
|
|
2024
Q4 | $105K | Buy |
+18,346
| New | +$105K | ﹤0.01% | 1038 |
|
|
2022
Q4 | – | Sell |
-6,291
| Closed | -$326K | – | 1277 |
|
|
2022
Q3 | $326K | Buy |
+6,291
| New | +$326K | 0.01% | 1133 |
|
|
2022
Q1 | $527K | Buy |
7,399
+620
| +9% | +$44.2K | 0.01% | 1061 |
|
|
2021
Q4 | $507K | Buy |
6,779
+2,610
| +63% | +$195K | 0.01% | 910 |
|
|
2021
Q3 | $237K | Sell |
4,169
-4,495
| -52% | -$256K | ﹤0.01% | 1484 |
|
|
2021
Q2 | $381K | Buy |
8,664
+2,652
| +44% | +$117K | 0.01% | 1273 |
|
|
2021
Q1 | $297K | Buy |
+6,012
| New | +$297K | 0.01% | 1294 |
|
|
2020
Q4 | – | Sell |
-16,698
| Closed | -$764K | – | 1528 |
|
|
2020
Q3 | $764K | Sell |
16,698
-5,218
| -24% | -$239K | 0.02% | 735 |
|
|
2020
Q2 | $1.1M | Buy |
+21,916
| New | +$1.1M | 0.05% | 428 |
|